Read Our Latest Analysis on VERA Vera Therapeutics Stock Down 0.5 % The company has a market capitalization of $2.19 billion, a P/E ratio of -13.25 and a beta of 1.15. The company has a debt-to ...
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases.
BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted inducement awards consisting of a ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Vera Therapeutics shares are trading lower by 7.3% Monday afternoon. The company announced an exclusive license agreement with Stanford University for VT-109. Get Wall Street's Hottest Chart Every ...
Vera Therapeutics, Inc., a late clinical-stage biotechnology company focused on treatments for serious immunological diseases, announced that its management will present at the 43rd Annual J.P ...
Vera Therapeutics BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted inducement ...
A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website. Vera Therapeutics is a late clinical-stage ...